Department of CardiologyNephrology and EndocrinologyDepartment of ResearchNordsjaellands Hospital, Nordsjællands University Hospital, Dyrehavevej 29, 3400 Hilleroed, DenmarkInstitute of Clinical StudiesUniversity of Aarhus, Aarhus, DenmarkClinical Research UnitSteno Diabetes Center, Gentofte, DenmarkDepartment of PaediatricsHvidovre Hospital, Copenhagen University Hospital, Hvidovre, DenmarkDepartment of MedicineCopenhagen University Hospital, Gentofte, DenmarkDepartment of Physiology and Nuclear MedicineFrederiksberg Hospital, Copenhagen University Hospital, Frederiksberg, DenmarkInstitute of Clinical MedicineUniversity of Copenhagen, Copenhagen, Denmark
Department of CardiologyNephrology and EndocrinologyDepartment of ResearchNordsjaellands Hospital, Nordsjællands University Hospital, Dyrehavevej 29, 3400 Hilleroed, DenmarkInstitute of Clinical StudiesUniversity of Aarhus, Aarhus, DenmarkClinical Research UnitSteno Diabetes Center, Gentofte, DenmarkDepartment of PaediatricsHvidovre Hospital, Copenhagen University Hospital, Hvidovre, DenmarkDepartment of MedicineCopenhagen University Hospital, Gentofte, DenmarkDepartment of Physiology and Nuclear MedicineFrederiksberg Hospital, Copenhagen University Hospital, Frederiksberg, DenmarkInstitute of Clinical MedicineUniversity of Copenhagen, Copenhagen, Denmark Department of CardiologyNephrology and EndocrinologyDepartment of ResearchNordsjaellands Hospital, Nordsjællands University Hospital, Dyrehavevej 29, 3400 Hilleroed, DenmarkInstitute of Clinical StudiesUniversity of Aarhus, Aarhus, DenmarkClinical Research UnitSteno Diabetes Center, Gentofte, DenmarkDepartment of PaediatricsHvidovre Hospital, Copenhagen University Hospital, Hvidovre, DenmarkDepartment of MedicineCopenhagen University Hospital, Gentofte, DenmarkDepartment of Physiology and Nuclear MedicineFrederiksberg Hospital, Copenhagen University Hospital, Frederiksberg, DenmarkInstitute of Clinical MedicineUniversity of Copenhagen, Copenhagen, Denmark Department of CardiologyNephrology and EndocrinologyDepartment of ResearchNordsjaellands Hospital, Nordsjællands University Hospital, Dyrehavevej 29, 3400 Hilleroed, DenmarkInstitute of Clinical StudiesUniversity of Aarhus, Aarhus, DenmarkClinical Research UnitSteno Diabetes Center, Gentofte, DenmarkDepartment of PaediatricsHvidovre Hospital, Copenhagen University Hospital, Hvidovre, DenmarkDepartment of MedicineCopenhagen University Hospital, Gentofte, DenmarkDepartment of Physiology and Nuclear MedicineFrederiksberg Hospital, Copenhagen University Hospital, Frederiksberg, DenmarkInstitute of Clinical MedicineUniversity of Copenhagen, Copenhagen, Denmark.
Endocr Connect. 2015 Jun;4(2):128-35. doi: 10.1530/EC-15-0034. Epub 2015 May 8.
Despite aggressive treatment of cardiovascular disease (CVD) risk factors individuals with type 2 diabetes (T2D) still have increased risk of cardiovascular morbidity and mortality. The primary aim of this study was to examine the cross-sectional association between total (25-hydroxy vitamin D (25(OH)D)) and risk of CVD in patients with T2D. Secondary objective was to examine the association between 25(OH)D and bone health. A Danish cohort of patients with T2D participating in a randomised clinical trial were analysed. In total 415 patients (68% men, age 60±9 years (mean±s.d.), duration of diabetes 12±6 years), including 294 patients (71%) treated with insulin. Carotid intima-media thickness (IMT) and arterial stiffness (carotid artery distensibility coefficient (DC) and Young's elastic modulus (YEM)) were measured by ultrasound scan as indicators of CVD. Bone health was assessed by bone mineral density and trabecular bone score measured by dual energy X-ray absorptiometry. In this cohort, 214 patients (52%) were vitamin D deficient (25(OH)D <50 nmol/l). Carotid IMT was 0.793±0.137 mm, DC was 0.0030±0.001 mmHg, YEM was 2354±1038 mmHg and 13 (3%) of the patients were diagnosed with osteoporosis. A 25(OH)D level was not associated with carotid IMT or arterial stiffness (P>0.3) or bone health (P>0.6) after adjustment for CVD risk factors. In conclusion, 25(OH)D status was not associated with carotid IMT, arterial stiffness or bone health in this cohort of patients with T2D. To explore these associations and the association with other biomarkers further, multicentre studies with large numbers of patients are required.
尽管对心血管疾病(CVD)危险因素进行了积极治疗,但 2 型糖尿病(T2D)患者的心血管发病率和死亡率仍较高。本研究的主要目的是探讨 T2D 患者 25-羟维生素 D(25(OH)D)总量与 CVD 风险的横断面相关性。次要目的是探讨 25(OH)D 与骨健康的关系。对参与随机临床试验的丹麦 T2D 患者队列进行了分析。共纳入 415 名患者(68%为男性,年龄 60±9 岁(均值±标准差),糖尿病病程 12±6 年),其中 294 名患者(71%)接受胰岛素治疗。颈动脉内膜中层厚度(IMT)和动脉僵硬度(颈动脉扩张系数(DC)和杨氏弹性模量(YEM))通过超声扫描测量,作为 CVD 的指标。骨健康通过双能 X 线吸收法测量骨矿物质密度和小梁骨评分来评估。在该队列中,214 名患者(52%)存在维生素 D 缺乏(25(OH)D <50nmol/L)。颈动脉 IMT 为 0.793±0.137mm,DC 为 0.0030±0.001mmHg,YEM 为 2354±1038mmHg,3%(13 名)的患者被诊断为骨质疏松症。在调整 CVD 危险因素后,25(OH)D 水平与颈动脉 IMT 或动脉僵硬度(P>0.3)或骨健康(P>0.6)无关。总之,在该 T2D 患者队列中,25(OH)D 状态与颈动脉 IMT、动脉僵硬度或骨健康无关。为了进一步探讨这些关联以及与其他生物标志物的关联,需要开展有大量患者参与的多中心研究。